Q-omics provides the consensus-scored DRD5P1 profile across patient tissues and cancer cell-line models. DRD5P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DRD5P1 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, DRD5P1 RNA expression shows 6,109 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, STAD, and UCEC as cancer lineages where DRD5P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DRD5P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DRD5P1 survival associations across molecular data types. DRD5P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DRD5P1 RNA expression–survival associations across cancer types. High DRD5P1 expression shows unfavorable associations in KIRC, BLCA, LIHC and ACC, but favorable associations in PAAD and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for DRD5P1 RNA expression.
This table summarizes DRD5P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for DRD5P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DRD5P1 shows lower tumor expression in STAD, BRCA, ESCA and KIRP. The STAD box plot shows higher DRD5P1 RNA expression in normal versus tumor tissue (log2 FC = −0.241, t-test p < 0.001).
This table shows molecular features associated with DRD5P1 in patient tissues and cancer cell lines. In patient samples, DRD5P1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
